Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Panelists discuss the diagnostic criteria for atopic dermatitis (AD), highlighting challenges in diagnosis due to the disease’s heterogeneity across factors like age, skin color, and other variables, and explore how this complexity can lead to misdiagnosis or late diagnosis; they also share tips for diagnosing AD, determining disease severity, and incorporating patient-reported outcomes into severity assessments, while examining how advances in treatment and understanding have shaped current perspectives on AD severity.

Considerations for Diagnosing Atopic Dermatitis and Assessing Severity

This analysis highlights the transcriptomic patterns of chronic hand eczema, indicating the potential of novel drug targets.

Study Highlights Findings on Chronic Hand Eczema from Skin Tape Stripping 

New topline data released by Inmagene indicate positive findings from a phase 2a trial on IMG-007 for moderate-to-severe atopic dermatitis.

New Phase 2a Findings Released on IMG-007 Treatment of Atopic Dermatitis

This analysis using worldwide data from GBD 2021 indicates that the global burden of eczema in children has gradually risen and has been projected to continue increasing.

Global Atopic Dermatitis Among Children Projected to Rise Over 50 Years

Panelists discuss the pathophysiology of atopic dermatitis (AD), focusing on the role of type 2 inflammation, and explore how AD can serve as an entry point to the atopic march in children, leading to other allergic diseases such as food allergies, asthma, and allergic rhinitis, including early indicators that may predict future comorbidities.

Overview of Atopic Dermatitis Pathophysiology and Atopic March in Children

These data expanded upon limited real-world data on retention of dupilumab past 2 years of treatment for patients with atopic dermatitis.

Study Highlights 5-Year Real-World Survival of Dupilumab for Atopic Dermatitis

These interim data resulted from the JADE REAL study, with 72-week results suggesting rapid improvements in eczema severity for adults and adolescents.

Study Highlights Interim Results on Abrocitinib for Adolescents, Adults with Atopic Dermatitis

Why Some Dermatologists Are Adopting JAKs for Uncontrolled Moderate-to-Severe Atopic Dermatitis

In a recent study, tralokinumab demonstrates effectiveness and safety for treating moderate-to-severe atopic dermatitis in adults who are dupilumab naïve and non-naïve.

Tralokinumab Effectively Treats Moderate-to-Severe Atopic Dermatitis: Real-World Data

Findings suggest an association between food allergies and atopic dermatitis control and persistence.

Pediatric Food Allergies Linked to Uncontrolled Atopic Dermatitis, Long-Term Prognosis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.